-
Product Insights
Likelihood of Approval Analysis for Neurofibromatoses Type I (Von Recklinghausen’s Disease)
Overview How likely is it that the drugs in Neurofibromatoses Type I (Von Recklinghausen's Disease) will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Neurofibromatoses Type I (Von Recklinghausen's Disease) Overview Neurofibromatosis...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ulixertinib in Neurofibromatoses Type I (Von Recklinghausen’s Disease)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ulixertinib in Neurofibromatoses Type I (Von Recklinghausen's Disease) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ulixertinib in Neurofibromatoses Type I (Von Recklinghausen's Disease)...
-
Product Insights
Von Willebrand Disease (vWD) – Drugs In Development, 2023
Global Markets Direct’s, ‘Von Willebrand Disease (vWD) - Drugs In Development, 2023’, provides an overview of the Von Willebrand Disease (vWD) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Von Willebrand Disease (vWD), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
Neurofibromatoses Type I (Von Recklinghausen’s Disease) – Drugs In Development, 2023
Global Markets Direct’s, ‘Neurofibromatoses Type I (Von Recklinghausen’s Disease) - Drugs In Development, 2023’, provides an overview of the Neurofibromatoses Type I (Von Recklinghausen’s Disease) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Neurofibromatoses Type I (Von Recklinghausen’s Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – MK-3795 in Von Hippel-Lindau Syndrome
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - MK-3795 in Von Hippel-Lindau Syndrome report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. MK-3795 in Von Hippel-Lindau Syndrome Drug Details: MK-3795 is under development...
-
Product Insights
Likelihood of Approval Analysis for Pheochromocytoma
Overview How likely is it that the drugs in Pheochromocytoma will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Pheochromocytoma Overview Pheochromocytoma is a rare, usually non-cancerous (benign) tumor that develops from...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – NFX-179 in Neurofibromatoses Type I (Von Recklinghausen’s Disease)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - NFX-179 in Neurofibromatoses Type I (Von Recklinghausen's Disease) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. NFX-179 in Neurofibromatoses Type I (Von Recklinghausen's Disease)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ALXN-1910 in Neurofibromatoses Type I (Von Recklinghausen’s Disease)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ALXN-1910 in Neurofibromatoses Type I (Von Recklinghausen's Disease) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ALXN-1910 in Neurofibromatoses Type I (Von Recklinghausen's Disease)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – TLM-101 in Neurofibromatoses Type I (Von Recklinghausen’s Disease)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - TLM-101 in Neurofibromatoses Type I (Von Recklinghausen's Disease) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. TLM-101 in Neurofibromatoses Type I (Von Recklinghausen's Disease)...